Fig. 5: Tumor antigen-reactive T cells are present in both NKG2A− and NKG2A+ DP CD8 TILs. | Nature Communications

Fig. 5: Tumor antigen-reactive T cells are present in both NKG2A and NKG2A+ DP CD8 TILs.

From: IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells

Fig. 5

a In vitro expanded CD8 TILs were cocultured with autologous APCs electroporated with the indicated HPV16 E constructs. T cell reactivity was assessed by 4-1BB upregulation after 20 hours of culture. Data for one representative patient with HPV+ HNSCC are shown. b Summary of the reactivity of NKG2A and NKG2A+ DP CD8 TILs to HPV16 E proteins for 6 patients with HPV+ HNSCC, as measured by 4-1BB upregulation. The colors in the heatmap legend represent the frequency of 4-1BB+ cells. c NKG2A and NKG2A+ DP CD8 TILs isolated from one HPV+ HNSCC patient were cultured with autologous APCs pulsed with DMSO or the peptide 14 of the HPV16 E6 peptide pool and reactivity was measured by 4-1BB upregulation. d NKG2A and NKG2A+ DP CD8 TILs isolated from one HNSCC patient (left) and one CRC patient (right) were cultured with autologous APCs pulsed with DMSO or the indicated mutated peptide and reactivity was measured by 4-1BB upregulation.

Back to article page